Proven results
Controlled mean Glycosylated Hemoglobin
The average estimated* glycosylated haemoglobin of users with regular use of SocialDiabetes is 6.7% for type 1 and 6.5% for type 2.
![Proven results from the use of SocialDiabetes. results_hba1c_socialdiabetes](/images/chart-en.png)
Reduction of up to 1% of Glycosylated Hemoglobin in 3 months
Users with type 1 diabetes with a high initial glycosylated haemoglobin (HbA1c > 8%), experience, on average, a reduction of 1% after 3 months of continuous use of SocialDiabetes. In the case of users with type 2 diabetes, this reduction rises to 2%.
![Reduction of hba1c in three months. SocialDiabetes. reduccion_hba1c_socialdiabetes](/images/chart2-en.png)
Join the largest community of users.
Thanks to SocialDiabetes our users ...
![Count carbohydrates. SocialDiabetes carbohydrates_socialdiabetes](/images/spiga.png)
Have eaten more than 7 million servings of carbohydrates.
![Insulin. SocialDiabetes insulin_socialdiabetes](/images/gota.png)
More than 141 liters of rapid insulin have been put in.
![Diabetes pills. SocialDiabetes metformin_socialdiabetes](/images/pill.png)
Have taken more than 205,000 pills
Awards
![Best mobile application in health - WSA United Nations. SocialDiabetes logo_wsa](/images/brands/wsa.png)
Best mobile application in the health category - WSA United Nations
![Best Health App iSYS Foundation. SocialDiabetes logo_foundation_isys](/images/brands/isys.png)
Best Health App 2015-2019 iSYS Foundation
![Winners MunichRE InsurTech Accelerator. SocialDiabetes logo_munichre](/images/brands/munich-re.png)
Winners MunichRE InsurTech Accelerator 2016
Collaborators
![A.Menarini Diagnostics collaborator SocialDiabetes logo_menarini_diagnostics](/images/brands/menarini.png)
![MiceLab collaborator SocialDiabetes logo_micelab](/images/brands/micelab.png)
![Munich RE Social PartnerDiabetes logo_munichre](/images/brands/munich-re-grey.png)
![University of Oxford collaborator SocialDiabetes logo_university_of_oxford](/images/brands/university-of-oxford.png)
![European Commission partner SocialDiabetes european_commission_logo](/images/brands/com-eu.png)
![EIT Health partner SocialDiabetes eit_logo](/images/brands/EIT_Health.png)
![Agamatrix partner SocialDiabetes agamatrix](/images/brands/agamatrix-logo.png)
![European Commission partner SocialDiabetes eu_logo](/images/brands/EU.png)
![Farmalisto partner SocialDiabetes farmalisto_logo](/images/brands/Farmalisto-logo.png)
![Innovation Zed partner SocialDiabetes einnovation_zed_logo](/images/brands/innovation_zed.png)
![Ascencia partner SocialDiabetes ascensia_logo](/images/brands/ascensia_logo.png)
![Novo Nordisk partner SocialDiabetes novo_nordisk_logo](/images/brands/novo.png)
NextGenerationEU
PROJECT: Towards a new generation of digital diabetes solutions: Artificial pancreas for patients with continuous monitoring devices and smart pen insulin. (2022 - 2025). Reference: CPP2021-008659. Funded by MCIN - 656.441,06€. P.I. Josep Vehí. Participants: SocialDiabetes, UdG